Global Phase III Clinical Trial - VIABLE

SOTIO is currently testing the safety and efficacy of SOTIO® DCVAC/PCa treatment in an extensive global multi-center Phase III clinical trial in prostate cancer called the VIABLE study, which was launched in 2014. 

The VIABLE study recruited patients through cooperation with medical centers in 21 European countries and the United States. SOTIO enrolled a total of 1,182 prostate cancer patients in the study. The acronym VIABLE is derived from the description of this trial: actiVImmunotherApy using dendritic cell-Based treatment for Late stage prostatE cancer. For more information about the clinical trial please visit VIABLE Study website.

Description of Global Phase III - VIABLE clinical trial:

Clinical Trial SP005 VIABLE (Eudra CT: 2012-002814-38: IND: 015255) is a randomized, double-blind, multi-center parallel-group Phase III study designed to assess the efficacy and safety of DCVAC/PCa added to standard of care in comparison with placebo in men with metastatic castration-resistant prostate cancer eligible for first-line chemotherapy. For more information please visit